INTRODUCTION

Serum assays are often combined with gastroscopic examination in gastric cancer screening. Gastric biopsy allows for accurate detection of the presence of Helicobacter pylori; however, false-negative findings are not rare. Indeed, the risk of false-negative Giemsa staining results is increased in patients with decreased gastric secretory ability. Therefore, in addition to gastroscopy, serum anti-H. pylori immunoglobulin G (IgG) titers are often monitored, along with serum pepsinogen (PG) levels. Although the specificity of the serology test was lower, the sensitivity was higher than in other H. pylori tests.

Gastroscopy findings and serum assay results help predict the status of H. pylori infection. However, in an H. pylori-seroprevalent population, a considerable proportion (22.2%) of seronegative subjects had past infection. Moreover, seronegative subjects often demonstrate closed-type (22.8%) or open-type (6.0%) atrophic gastritis, even in the absence of gastric corpus atrophy (serum PG I ≤ 70 ng/mL and PGI/II ≤ 3). A diffuse red fundal appearance, mucosal swelling, nontransparent sticky mucus, and hypertrophic gastric rugae in the corpus are well-known findings of active H. pylori infection; alternatively, regular arrangement of collecting venules (RAC), linear streaks, and fundic gland polyps are more common in the absence of H. pylori infection. It is important to collect data of false-seropositive subjects without infection and those infected with H. pylori during the follow-up of seronegative individuals. A recent study indicated...
that the annual seroconversion rate was 2.79%, and that living with an *H. pylori*-infected individual was a risk factor for sero-
conversion in Koreans. It is important to accurately identify *H. pylori* infection among seroconverted subjects; however, data during screening for gastric cancer are limited in Korea. In this study, we aimed to accurately determine the number of subjects accurately diagnosed with *H. pylori* after seroconversion in follow-up tests. Furthermore, we aimed to identify the differences between *H. pylori*-infected subjects and those with false-seropositive results.

**SUBJECTS AND METHODS**

**Selection of study subjects**

After our previous study, we followed-up a consecutive series of Koreans subjects until 2019 who were *H. pylori*-se-
ronegative and underwent screening for gastric cancer at our center between 2010 and 2014. Among the subjects regist-
tered at ClinicalTrials.gov (NCT01824953), only those who were followed up using the same *H. pylori* serologic test for ≥ 24 months were analyzed in this study. Subjects with a re-
cent history of *H. pylori* eradication within the past two years, renal failure, or a history of gastrectomy were excluded from the study.

This study was performed at our center in accordance with the Helsinki Declaration after Institutional Review Board ap-
proval (KUH1010626). Informed consent was obtained from the subjects before performing gastric cancer screening tests using GIF-H260, GIF-H290 (Olympus, Tokyo, Japan), or EG-
2990i (Pentax, Tokyo, Japan) endoscopes; serum PG assay (HBi Co., Anyang, Korea); and serum anti-*H. pylori* IgG Chorus as-
say (DIESSE Diagnostica Senese, Siena, Italy). All digital data were collected using ethical methods.

**Assessment for endoscopy and gastric biopsy findings**

Based on the Kyoto classification scoring system for gastri-
tis, the presence and degree of chronic atrophic gastritis (A), metaplastic gastritis (IM), hypertrophic gastric rugae (H), nodular gastritis (N), and diffuse red (DR) fundal appearance were scored from 0 to 8. Briefly, chronic atrophic gastritis was scored as A0 (none or closed-type 1), A1 (closed-type 2 or 3), and A2 (open-type). Metaplastic gastritis was scored as IM0 (none), IM1 (limited), or IM2 (extensive). Hypertrophic rugae were scored as H0 (absent) and H1 (present). Nodular gastritis was scored as N0 (absent) or N1 (present). The diffuse red fundal appearance was scored as DR0 (none), DR1 (mild), and DR2 (severe).

Endoscopic biopsies were performed on lesions with abnor-
mal shapes or discoloration. Gastric biopsy specimens were subjected to hematoxylin and eosin staining, as well as Giemsa staining. *H. pylori*-related gastric biopsy findings have been reported as previously described. *H. pylori* infection was con-
irmed based on positive Giemsa staining.

**Determining *H. pylori* infection status**

Infection status was classified as *H. pylori*-naïve, past, or current. Past infection was defined as either a history of erad-
ication, *H. pylori*-related changes on gastroscopy, or gastric biopsy findings. In order to exclude subjects with spontaneous regression or unintended eradication, classification of *H. pylori-*naïve stomachs was based on the following criteria: (1) no previous diagnosis of *H. pylori* infection, (2) negative findings on invasive and noninvasive *H. pylori* tests, (3) absence of gastric corpus atrophy (serum PG I ≤ 70 ng/mL and PG I/II ratio ≤ 3), (4) absence of gastric atrophy, intestinal metaplasia, neutrophil, or *H. pylori* in the biopsied specimen (only a mild degree of mononuclear cell infiltration was permitted), and (5) regular arrangement of collecting venules on gastroscopy without evidence of past infection (either the presence of metaplastic gastritis, gastric xanthoma, or advanced atrophic gastritis ≥ closed-type 2).

**Interpretation of *H. pylori* serologic test**

Seropositivity was diagnosed when anti-*H. pylori* IgG level was ≥ 12.0 AU/mL, with 100% sensitivity and 75% specificity based on our previous study. Seroconversion was considered when a seronegative subject showed seropositive test find-
ings in the follow-up tests. The subjects were finally classified into subjects without seroconversion (persistent seronegative group) and subjects with seroconversion (seropositive group).

**Primary outcome measurement**

Accurate detection of *H. pylori* infection was considered the primary endpoint of this study. Current infection was di-
agnosed based on a positive Giemsa staining finding. Sero-
negative subjects with positive Giemsa staining findings were excluded, since non-*H. pylori Helicobacter or Campylobacter* may show false-positive Giemsa staining findings. In these cases, follow-up *H. pylori* tests (i.e., 13C-urea breath test [UBT] with the aid of the POCon® [Otsuka Electronics Co., Ltd., Osaka, Japan]) were performed for confirmation to verify new infection in *H. pylori*-naïve subjects and to identify reinfection in subjects with past infection. Recrudescence was not consid-
ered in this study since all subjects with a history of successful eradication showed seronegative results for ≥ 24 months after eradication of the remote *H. pylori* infection.
Secondary outcome measurement
Seroconversion in follow-up tests was considered as the secondary endpoint. Seroconverted subjects without evidence of ongoing *H. pylori* infection were regarded as having false-positive test findings. The absence of infection after seroconversion was confirmed either by a negative $^{13}$C-UBT result or by spontaneous seroreversion of *H. pylori* with persistent RAC in follow-up tests.

Statistical analysis
Differences between the two groups were analyzed using the *Student’s t*-test for continuous variables and the *chi-square* test for categorical variables. Continuous variables with symmetrical distribution are presented as mean ± standard deviation, and categorical variables are presented as the number of subjects with proportion (%). For continuous variables with asymmetrical distribution, data were presented as medians with ranges using the Kruskal-Wallis test. The Fisher’s exact test was used for categorical variables with an asymmetrical distribution. Differences between the initial and follow-up tests were analyzed using the Wilcoxon signed-rank test. All statistical analyses were performed using PASW statistics (version 24.0; SPSS Inc., Chicago, IL, USA). Statistical significance was set at $p < 0.05$.

RESULTS

Characteristics of the included *H. pylori*-seronegative subjects
A total of 407 seronegative subjects underwent follow-up tests using the same serum anti-*H. pylori* IgG Chorus assay. Baseline characteristics and test findings are summarized in Table 1.

Incidence of seroconversion
During the mean follow-up of 57.7 ± 21.4 months, 61 (15.0%) of 407 seronegative subjects showed seroconversion (Fig. 1). The annual seroconversion rate was 3.3%. The seroconverted subjects had a longer follow-up period (68.6 ± 23.8 months vs. 55.8 ± 20.4 months, $p < 0.001$) and a higher initial serology titer than those without seroconversion (6.7 ± 1.6 AU/mL vs. 5.7 ± 1.3 AU/mL, $p < 0.001$).

Seropositive subjects with *H. pylori* infection in the follow-up tests
*H. pylori* infection was detected in six (9.8%) of 61 seroconverted subjects. Therefore, *H. pylori* infection was observed in 2.0% (0.42% per year) of seronegative subjects during screening for gastric cancer. The initial and follow-up test results of the six infected subjects are summarized in Table 2.

Changes in endoscopic findings were observed in an *H. pylori*-naïve subject with new infection (Fig. 2), as well as in subjects with reinfection in whom eradication therapy was previously performed (Fig. 3), and in a subject with unintended eradication (Fig. 4). Compared to the initial endoscopic findings, all infected subjects demonstrated diffuse red fundal appearance. The total Kyoto classification scores ($p < 0.001$) and diffuse red fundal appearance scores ($p < 0.001$) increased significantly.

False-seropositive subjects in the follow-up tests
Compared to the initial serologic titers, follow-up serologic titers showed a significant increase from 6.4 AU/mL to 22.0 AU/mL ($p < 0.001$). However, there were no significant changes in the serum PG assay findings (Table 3). A small increase was observed in the Kyoto classification scores for gastritis (from 0.13 to 0.30, $p = 0.006$) and metaplastic gastritis scores (from 0.11 to 0.27, $p = 0.006$); however, none of these false-seropositive subjects exhibited a positive *H. pylori* test result in follow-up tests. $^{13}$C-UBT was performed in nine subjects, and it was negative in this group of subjects. Furthermore, 52 of 55 false-seropositive subjects showed persistent RAC on follow-up endoscopy. Spontaneous seroreversion of *H. pylori* was observed in 31 subjects who underwent the same serological follow-up procedure during screening for gastric cancer.

Difference between the follow-up test findings in the infected and false-seropositive subjects
The median serologic titer increased from 6.5 AU/mL to 132.7 AU/mL in the seropositive subjects with *H. pylori* infection ($p = 0.021$). Hence, the serology titer was significantly higher among the infected subjects than the false-seropositive subjects (132.7 AU/mL vs. 22.0 AU/mL, $p < 0.001$) at the time of seroconversion (Table 3). Moreover, serum PG II levels were higher in the infected group than in the false-seropositive group (22.8 ± 10.5 ng/ml vs. 10.4 ± 5.3 ng/ml, $p < 0.001$), and serum PG I/II ratios were lower in the infected group than in the false-seropositive group (3.7 ± 1.1 vs. 6.2 ± 1.6, $p = 0.002$).

In the follow-up endoscopies, the infected subjects showed a significant increase in the Kyoto classification scores (2.75 vs. 0.30, $p < 0.001$), chronic atrophic gastritis scores (0.60 vs. 0.04, $p < 0.001$), metaplastic gastritis scores (1.00 vs. 0.27, $p < 0.001$), and diffuse red fundal appearance scores (1.33 vs. 0, $p < 0.001$) (Table 3). All infected subjects had diffuse red fundal appearance; meanwhile, this finding was not observed in any of the false-seropositive subjects ($p < 0.001$).
| Variables                                      | All subjects (n=407) | Follow-up serology test findings | p-value |
|-----------------------------------------------|----------------------|----------------------------------|---------|
|                                               |                      | Without seroconversion (n=346)   | With seroconversion (n=61) |         |
| Age (years)                                   | 50.9±10.0            | 50.7±10.0                        | 52.2±9.8 | 0.279   |
| Sex (male)                                    | 253 (62.1%)          | 211 (61.0%)                      | 42 (68.9%) | 0.243   |
| Body mass index (kg/m²)                       | 24.3±3.1             | 24.3±3.2                         | 24.8±2.9 | 0.255   |
| Past \( H. pylori \) infection               | 155 (38.1%)          | 127 (36.7%)                      | 28 (45.9%) | 0.173   |
| \( H. pylori \) eradication history           | 127 (31.2%)          | 102 (29.5%)                      | 25 (41.0%) | 0.074   |
| Intended eradication                          | 28 (6.9%)            | 25 (7.2%)                        | 3 (4.9%)  | 0.783   |
| Comorbidities                                 |                      |                                  |         |
| Diabetes mellitus                             | 50 (12.3%)           | 41 (11.8%)                       | 9 (14.8%) | 0.542   |
| Hypertension                                  | 113 (27.8%)          | 93 (26.9%)                       | 20 (32.8%) | 0.342   |
| Coronary heart disease                        | 25 (6.1%)            | 18 (5.2%)                        | 7 (11.5%) | 0.078   |
| Recent drug intake                            |                      |                                  |         |
| Nonsteroidal anti-inflammatory drug           | 32 (7.9%)            | 26 (7.5%)                        | 6 (9.8%)  | 0.604   |
| Antithrombotic agents including aspirin      | 49 (12.0%)           | 42 (12.1%)                       | 7 (11.5%) | 0.883   |
| Acid suppressants                             | 5 (1.2%)             | 4 (1.2%)                         | 1 (1.6%)  | 0.558   |
| Initial test findings                         |                      |                                  |         |
| Serum anti-\( H. pylori \) IgG (AU/mL)        | 5.9±1.4              | 5.7±1.3                          | 6.7±1.6  | < 0.001 |
| Serum pepsinogen I (ng/ml)                    | 52.6±2.7             | 51.8±20.1                        | 56.9±28.8 | 0.092   |
| Serum pepsinogen II (ng/ml)                   | 9.8±4.3              | 9.5±4.0                          | 10.4±5.4 | 0.139   |
| Serum pepsinogen I/II ratio                   | 5.6±1.4              | 5.6±1.4                          | 5.7±1.5  | 0.934   |
| Total follow-up period (months)               | 57.7±21.4            | 55.8±20.4                        | 68.6±23.8 | < 0.001 |
| Follow-up test findings                       |                      |                                  |         |
| Serum anti-\( H. pylori \) IgG (AU/mL)        | 6.1 (5–200)          | 5.6 (5–11.9)                     | 22.7 (12.1–200) | < 0.001 |
| Serum pepsinogen I (ng/ml)                    | 55.7±25.1            | 54.5±23.1                        | 62.5±31.5 | 0.022   |
| Serum pepsinogen II (ng/ml)                   | 8.4 (3–36.6)         | 8.3 (3–36.6)                     | 9.6 (3.8–35.6) | 0.001   |
| Serum pepsinogen I/II ratio                   | 6.3±2.0              | 6.4±2.1                          | 6.0±1.7  | 0.197   |

\( H. pylori \), Helicobacter pylori; IgG, immunoglobulin G.

Continuous variables are presented as mean±standard deviation using the t-test, and categorical variables are presented as number of the subjects with proportion (%) using the Chi-square test. For continuous variables with asymmetrical distribution, data are presented as median with ranges using the Kruskal-wallis test. For categorical variables with asymmetrical distribution, Fisher's exact test was used.

Unintended eradication or spontaneous regression of \( H. pylori \) was considered when intestinal metaplasia, advanced atrophic gastritis, or gastric xanthoma was observed in subjects without eradication history.
Kim YJ et al. Infection in Seroconverted Subjects

Fig. 1. Flowchart of this study. A total of 407 consecutive Helicobacter pylori (H. pylori)-seronegative subjects were included in our study. During the mean follow-up period of 57.7±21.4 months, 61 subjects showed seroconversion; meanwhile, seronegative results persisted in 346 subjects. H. pylori infection was observed in six (9.8%) of 61 seroconverted subjects.

Table 2. Initial and Follow-Up Test Findings of the Six Seroconverted Subjects with Helicobacter pylori Infection

| Initial infection status | Sex / age | Comorbidity | Serology (AU/mL) | PG I (ng/ml) | PG II (ng/ml) | PG I/II ratio | Kyoto classification score for gastritis |
|-------------------------|-----------|-------------|------------------|-------------|-------------|--------------|---------------------------------------|
| H. pylori-naive         | M/55      | DM, HTN     | Initial 6.4 F/U 21.7 | Initial 69.5 F/U 85.1 | Initial 18.9 F/U 22.5 | Initial 3.7 F/U 3.8 | Initial 0 (A0 IM0 H0 N0 DR0) F/U 2 (A0 IM0 H0 N0 DR2) |
|                         |           |             | Initial 9.4 F/U 161.5 | Initial 46.4 F/U 97.2 | Initial 10.3 F/U 29.8 | Initial 4.5 F/U 3.3 | Initial 3 (A1 IM2 H0 N0 DR0) F/U 5 (A1 IM2 H0 N0 DR2) |
| Previous eradication    | M/54      | HTN         | F/67             | F/66        | F/49        | M/53         |                                          |
| history                 |           |             | Initial 6.5 F/U > 200 | Initial 9.3 F/U 19.2 | Initial 5.8 F/U 107.2 | Initial < 5 F/U 158.1 |                                          |
|                         |           |             | Initial 4.4 F/U 161.5 | Initial 39.2 F/U 42.7 | Initial 33.7 F/U 66.1 | Initial 58.5 F/U 54.3 |                                          |
|                         |           |             | Initial 7.2 F/U 97.2  | Initial 8.1 F/U 7.6  | Initial 6.3 F/U 27.8  | Initial 12.2 F/U 13.6 |                                          |
|                         |           |             | Initial 29.8 F/U 116.0 | Initial 7.6 F/U 35.6 | Initial 27.8 F/U 6.3  | Initial 22.5 F/U 13.6 |                                          |
|                         |           |             | Initial 4.5 F/U 3.3  | Initial 4.9 F/U 5.6  | Initial 3.8 F/U 4.0  | Initial 2.4 F/U 4.0  |                                          |
|                         |           |             | Initial 3 (A1 IM2 H0 N0 DR0) | Initial 1 (A0 IM1 H0 N0 DR0) | Initial 1 (A0 IM1 H0 N0 DR0) | Initial 1 (A0 IM1 H0 N0 DR0) |                                          |
|                         |           |             | Initial 5 (A1 IM2 H0 N0 DR2) | Initial 2 (A0 IM1 H0 N0 DR1) | Initial 3 (A1 IM1 H0 N0 DR1) | Initial 2 (A0 IM1 H0 N0 DR1) |                                          |

CVA, cerebrovascular disease; DM, diabetes mellitus; F, female; F/U, follow-up; H. pylori, Helicobacter pylori; HTN, hypertension; M, male; PG, pepsinogen.

Chronic atrophic gastritis was scored as A0 (none or closed-type 1), A1 (closed-type 2 or 3), and A2 (open-type). Metaplastic gastritis was scored as IM0 (none), IM1 (limited), and IM2 (extensive). Hypertrophic rugae were scored as H0 (absent) and H1 (present). Nodular gastritis was scored as N0 (absent) and N1 (present). Diffuse redness was scored as DR0 (none), DR1 (mild), and DR2 (severe).

Unintended eradication was considered in this subject because intestinal metaplasia was observed in the gastric biopsied specimen.
Fig. 2. Development of diffuse red fundal appearance on follow-up endoscopy in a *Helicobacter pylori* (*H. pylori*)-naïve subject with new infection. (A) Initial endoscopic findings of the fundus and cardia. The Kyoto classification score was 0 (A0, IM0, H0, N0 DR0). Serum pepsinogen (PG) and serology assays showed normal results, as summarized in Table 2. (B) Findings of follow-up endoscopy performed after four years. Multiple tiny hemorrhagic spots were observed in the fundus with positive Giemsa staining. The Kyoto classification score increased from 0 to 2 (A0 IM0 H0 N0 DR2). Seroconversion in *H. pylori* antibodies (6.4 $\rightarrow$ 21.7 AU/mL) was reported with higher serum PG I (69.5 $\rightarrow$ 85.1 ng/ml) and PG II (18.9 $\rightarrow$ 22.5 ng/ml) levels compared to the initial test findings.

Fig. 3. Changes in the endoscopic findings of a subject who had a history of successful eradication four years prior to the initial visit. (A) Endoscopic findings of the fundus at the initial visit. The Kyoto classification score was 3 (A1 IM2 H0 N0 DR0). Successful eradication was confirmed by negative $^{13}$C-urea breath test findings. (B) Findings of follow-up endoscopy performed after six years. The development of diffuse red fundal appearance and positive Giemsa staining were observed. The Kyoto classification score increased from 3 to 5 (A1 IM2 H0 N0 DR2) with seroconversion (9.4 $\rightarrow$ 161.5 AU/mL). The serum pepsinogen (PG) I (46.4 $\rightarrow$ 97.2 ng/ml) and PG II (10.3 $\rightarrow$ 29.8 ng/ml) levels were higher compared to the initial test results, whereas the PG I/II ratio was lower (4.5 $\rightarrow$ 3.3).
Table 3. Difference between the Findings of Initial and Follow-Up Tests in the 61 Seroconverted Subjects

| Findings                              | False-seropositive subjects without infection (n=55) | Seropositive subjects with *H. pylori* infection (n=6) | p-value<sup>a</sup> |
|---------------------------------------|------------------------------------------------------|-------------------------------------------------------|---------------------|
|                                       | Initial | Follow-up | p-value<sup>b</sup> | Initial | Follow-up | p-value<sup>b</sup> |<br>**Serum anti-*H. pylori* IgG (AU/mL)**<br>6.4 (5–9.9) 22.0 (12.1–59.3) <0.001 | 6.5 (5–9.4) 132.7 (19.2–200) 0.021 | <0.001<br><br>**Serum pepsinogen I (ng/ml)**<br>57.8±30.0 60.9±31.9 0.383 | 48.8±13.1 76.9±27.6 0.062 | 0.547<br><br>**Serum pepsinogen II (ng/ml)**<br>10.3±5.5 10.4±5.3 0.991 | 11.1±4.4 22.8±10.5 0.054 | <0.001<br><br>**Serum pepsinogen I/II ratio**<br>5.8±1.5 6.2±1.6 0.076 | 4.6±0.6 3.7±1.1 0.153 | 0.002<br><br>**Total Kyoto classification score**<br>0.13 (0–2) 0.30 (0–2) 0.006 | 1.25 (0–3) 2.75 (2–5) 0.004 | <0.001<br><br>**Chronic atrophic gastritis score**<br>0.04 (0–2) 0.04 (0–2) NA | 0.33 (0–1) 0.60 (0–2) 0.363 | 0.001<br><br>**Metaplastic gastritis score**<br>0.11 (0–2) 0.27 (0–2) 0.006 | 1.00 (0–2) 1.00 (0–2) NA | 0.017<br><br>**Diffuse redness score**<br>0 0 NA | 0 1.33 (1–2) 0.001 | <0.001<br><br>**Interval till seropositivity (months)**<br>- 36.8±16.1 - | - 47.8±17.9 - | 0.302

*H. pylori*, *Helicobacter pylori*; IgG, immunoglobulin G; NA, not available due to the absence of changes between the initial and follow-up test findings.

Continuous variables are presented as mean±standard deviation using the *t*-test, and those with asymmetrical distribution are presented as median with ranges using the *Kruskal-wallis* test.

<sup>a</sup>*P*-values on the differences between the initial and follow-up test findings using the *Wilcoxon* signed-rank test.

<sup>b</sup>*P*-values on the differences in follow-up test findings between the false-seropositive and infected subjects.
DISCUSSION

In this study, we found that only 9.8% of the seroconverted subjects were accurately diagnosed with *H. pylori* infection. Although seroconversion occurred annually in 3.3% of the seronegative subjects during screening for gastric cancer, the majority (90.2%) of the subjects showed false-positive results without infection. A new *H. pylori* infection was observed in only 2.0% of the seronegative subjects during the mean follow-up period of 58 months (0.42% per year). All infected subjects showed diffuse redness in the fundus; however, it was not observed in any of the false-seropositive subjects. Therefore, diffuse redness in follow-up endoscopies could be considered an indicator for accurate detection of infection.

The seroconversion rate was related to a higher initial *H. pylori* titer and a longer follow-up period. Our findings are in accordance with those of a recent study that reported a link between high negative titers and the risk of gastric cancer based on the degree of atrophic gastritis. Moreover, follow-up serologic titers were useful for identifying infected subjects in this study. The serologic titers were significantly higher in the infected subjects than in the false-seropositive subjects. These findings are consistent with a recent study that demonstrated the usefulness of serum anti-*H. pylori* IgG titers for detection of reinfection. In summary, a high-negative IgG titer warrants serologic screening due to the higher risk of seroconversion and gastric cancer. Meanwhile, an increase in serologic titers in follow-up tests is indicative of ongoing *H. pylori* infection.

In this study, it was beneficial to include the results of the serum PG assay, as well as those of the serological tests. The serum assay was useful in discriminating subjects with *H. pylori*-infection from false-seropositive subjects. Increased serum PG II levels and serum anti-*H. pylori* IgG titers, as well as decreased PG I/II ratios, were observed in the infected subjects in follow-up tests. Previous studies have shown that increased PG II levels are more specific for detecting active *H. pylori* infection than PG I levels, and PG I levels increase frequently due to drugs, including aspirin. Differences in serum PG values between the eradicated and non-infected subjects were not detected at ≥24 months after successful eradication. High serum PG I and PG II levels indicate hyperchlorhydric stomachs, whereas low serum PG I levels and PG I/II ratios indicate hypochlorhydric stomachs with extensive atrophy. Consistent with these studies, PG II levels were significantly higher in infected subjects than in false-seropositive subjects; hence, the PG I/II ratio was significantly lower in infected subjects in this study. Serum assays cannot replace endoscopy for gastric cancer detection in a seroprevalent population; however, they are useful in discriminating between subjects at high-risk for diffuse-type gastric cancer (i.e., high-seropositive IgG titers with high PG II levels) and those with intestinal-type gastric cancer or gastric adenoma (i.e., low PG I levels with low PG I/II ratios), neuroendocrine tumors (i.e., extremely low PG I levels in patients with autoimmune gastritis, or high PG I levels in patients with Zollinger-Ellison syndrome), and *H. pylori*-negative gastric cancers.

Another notable finding of our study was diffuse red fundal appearance in infected subjects during follow-up endoscopy. Diffuse red fundal appearance represents the presence of infection, which progressively decreases after successful eradication. Increased hemoglobin index of the fundic mucosa during active inflammation appears to induce the diffuse red fundal appearance, since active inflammation due to *H. pylori* occurs more aggressively in the corpus than in the antrum. A recent study using C-UBT showed that the endoscopic Kyoto classification of gastritis was useful for diagnosing *H. pylori* infection, even in seronegative subjects with high serology titers. Furthermore, the Kyoto classification scoring system was useful in predicting reinfection in subjects in which the infection had been previously eradicated. The mean Kyoto score was 4.63 in subjects with active *H. pylori* infection, meanwhile, it was close to 0 in non-infected subjects in previous studies. The latter study showed that the endoscopy-based Kyoto score could detect false-seropositive subjects without infection, since the Kyoto score was 0 in 63.2% of the seropositive subjects with low seropositive titers. Consistent with these studies, infected subjects in our study showed a significant increase in the Kyoto classification scores at follow-up endoscopies. The development of diffuse red fundal appearance and positive Giemsa staining were detected in infected subjects, whereas none of these findings were observed in subjects with false-seropositive results.

There are some limitations in our study. For example, *H. pylori* infection was diagnosed based on positive Giemsa staining in seropositive subjects, and C-UBT was performed only in subjects who required confirmation. Most false-seropositive results were confirmed by spontaneous seroreversion and persistent RAC observed in follow-up endoscopies. Also, although image-enhanced endoscopy is useful for discriminating between *H. pylori*-active and inactive gastritis, it was not routinely performed in all screening endoscopies. Despite these limitations, we observed a diffuse red fundal appearance with higher Kyoto classification scores, *H. pylori* serology titers, and PG II levels in the infected subjects compared to the false-seropositive subjects.

In conclusion, seroconversion occurred in 3.3% of the seronegative subjects annually; however, only 9.8% were accurately...
diagnosed with *H. pylori* infection. The majority (90.2%) of the seroconverted subjects showed false positive results with lower serology titers, lower serum PG II levels, and higher PG I/II ratios compared to the infected subjects. Moreover, spontaneous seroreversion and RAC were observed in false-seropositive subjects; meanwhile, a significant increase in the Kyoto classification scores for gastritis was observed in the infected subjects due to a diffuse red fundal appearance. Active *H. pylori* infection should be considered in the presence of diffuse red fundal appearance during screening for gastric cancer.

**Conflicts of Interest**

The authors have no potential conflicts of interest.

**Funding**

This study was supported by the National Research Foundation (NRF) of Korea, funded by the Ministry of Education (NRF2016R1D1A1B02008937).

**Author Contributions**

Conceptualization: Sun-Young Lee

Data curation: Young Jung Kim, SYL, Jeong Hwan Kim, In-Kyung Sung, and Hyung Seok Park

Formal analysis: YJK, SYL

Funding acquisition: SYL

Investigation: YJK, SYL, JHK, IKS, HSP

Methodology: YJK, SYL, JHK, IKS, HSP

Project administration: SYL

Resources: YJK, SYL, JHK, IKS, HSP

Software: SYL

Supervision: SYL

Validation: YJK, SYL, JHK, IKS, HSP

Visualization: YJK, SYL, JHK, IKH, HSP

Writing-original draft: YJK

Writing-review & editing: SYL

**ORCID**

Young Jung Kim  https://orcid.org/0000-0003-4571-6021

Sun-Young Lee  https://orcid.org/0000-0003-4146-6686

Jeong Hwan Kim  https://orcid.org/0000-0002-2503-2688

In-Kyung Sung  https://orcid.org/0000-0002-3848-5571

Hyung Seok Park  https://orcid.org/0000-0003-3141-4858

**REFERENCES**

1. Shin CM, Kim N, Lee HS, et al. Validation of diagnostic tests for Helicobacter pylori with regard to grade of atrophic gastritis and/or intestinal metaplasia. Helicobacter 2009;14:512-519.

2. Kim JH, Lee SY, Lee SP, et al. The histologic detection of Helicobacter pylori in seropositive subjects is affected by pathology and secretory ability of the stomach. Helicobacter 2018;23:e12480.

3. Tu H, Sun L, Dong X, et al. Serum anti-Helicobacter pylori immunoglobulin G titer correlates with grade of histological gastritis, mucosal bacterial density, and levels of serum biomarkers. Scand J Gastroenterol 2014;49:259-266.

4. Bosch DE, Krumm N, Wener MH, et al. Serology is more sensitive than urea breath test or stool antigen for the initial diagnosis of Helicobacter pylori gastritis when compared with histopathology. Am J Clin Pathol 2020;154:255-265.

5. Lee SP, Lee SY, Kim JH, Sung IK, Park HS, Shim CS. Link between serum pepsinogen concentrations and upper gastrointestinal endoscopic findings. J Korean Med Sci 2017;32:796-802.

6. Kwon H, Lee SY, Kim JH, et al. ABC classification is less useful for older Koreans born before 1960. Gut Liver 2019;13:522-530.

7. Kishino T, Oyama T, Tomori A, Takahashi A, Shinohara T. Usefulness and limitations of a serum screening system to predict the risk of gastric cancer. Intern Med 2020;59:1473-1480.

8. Yoshii S, Mabe K, Watano K, et al. Validity of endoscopic features for the diagnosis of Helicobacter pylori infection status based on the Kyoto classification of gastritis. Dig Endosc 2020;32:74-83.

9. Jung JH, Choi KD, Han S, et al. Seroconversion rates of Helicobacter pylori infection in Korean adults. Helicobacter 2013;18:299-308.

10. Choi HS, Lee SY, Kim JH, et al. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasms. J Dig Dis 2014;15:293-298.

11. Kim GH. Endoscopic findings of Kyoto classification of gastritis. Korean J Helicobacter Up Gastrointest Res 2019;19:88-93.

12. Han HS, Lee SY, Oh SY, Moon HW, Cho H, Kim JH. Correlations of the gastric and duodenal microbiota with histological, endoscopic, and symptomatic gastritis. J Clin Med 2019;8:312.

13. Sugimoto M, Ban H, Ichikawa H, et al. Efficacy of the Kyoto classification of gastritis in identifying subjects at high risk for gastric cancer. Intern Med 2017;56:579-586.

14. Lee SY, Moon HW, Hur M, Yun YM. Validation of western Helicobacter pylori IgG antibody assays in Korean adults. J Med Microbiol 2015;64:513-518.

15. Seo TH, Lee SY, Uchida T, et al. The origin of non-Helicobacter pylori-related positive Giemsa stain in human gastric biopsy specimens. Dig Liver Dis 2011;43:23-27.

16. Inoue M, Sawada N, Goto A, et al.; JPHC Study Group. High-negative anti-Helicobacter pylori IgG antibody titers and long-term risk of gastric cancer: Results from a large-scale population-based cohort study in Japan. Cancer Epidemiol Biomarkers Prev 2020;29:420-426.

17. Lee JH, Kim N, Chung JI, et al. Long-term follow up of Helicobacter pylori IgG serology after eradication and reinfection rate of H. pylori in South Korea. Helicobacter 2008;13:288-294.

18. Massarrat S, Haj-Sheykholeslami A, Mohamadkhani A, et al. Pepsinogen II can be a potential surrogate marker of morphological changes in corpus before and after H. pylori eradication. Biomed Res Int 2014;2014:661607.

19. Shan J, Lei H, Shi W, Sun X, Tang Y, Ren C. High serum pepsinogen I and beta Helicobacter pylori infection are risk factors for aspirin-induced gastroduodenal injury. Dig Dis 2018;36:66-71.

20. Noh G, Kim N, Choi Y, et al. Long-term follow up of serum pepsinogens in subjects with gastric cancer or dysplasia after Helicobacter pylori eradication. J Gastroenterol Hepatol 2020;35:1540-1548.

21. Iijima K, Koike T, Ara N, et al. Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects. J Gastroenterol 2015;50:305-312.

22. Song HJ, Jang SJ, Yun SC, et al. Low levels of pepsinogen I and pepsinogen I/II ratio are valuable serologic markers for predicting extensive gastric corpus atrophy in patients undergoing endoscopic mucosectomy. Gut Liver 2010;4:475-480.

23. Lee SY. Helicobacter pylori-negative gastric cancer. Korean J Helicobacter Up Gastrointest Res 2020;21:30-21.

24. Kato M, Terao S, Adachi K, et al.; Study Group for Establishing Endoscopic Diagnosis of Chronic Gastritis. Changes in endoscopic findings of gastritis after cure of H. pylori infection: multicenter prospective trial. Dig Endosc 2013;25:264-273.

25. Kato T, Yagi N, Kamada T, Shimbo T, Watanabe H, Ida K; Study Group...
for Establishing Endoscopic Diagnosis of Chronic Gastritis. Diagnosis of Helicobacter pylori infection in gastric mucosa by endoscopic features: a multicenter prospective study. Dig Endosc 2013;25:508-518.
26. Toyoshima O, Nishizawa T, Arita M, et al. Helicobacter pylori infection in subjects negative for high titer serum antibody. World J Gastroenterol 2018;24:1419-1428.
27. Otani K, Watanabe T, Kosaka S, et al. Utility of Kyoto classification of gastritis in subjects with a high-negative titer of anti-Helicobacter pylori antibody during a medical check-up. J Clin Biochem Nutr 2020;67:317-322.
28. Toyoshima O, Nishizawa T, Yoshida S, et al. Endoscopy-based Kyoto classification score of gastritis related to pathological topography of neutrophil activity. World J Gastroenterol 2020;26:5146-5155.
29. Nishizawa T, Sakitani K, Suzuki H, et al. A combination of serum anti-Helicobacter pylori antibody titer and Kyoto classification score could provide a more accurate diagnosis of H. pylori. United European Gastroenterol J 2019;7:343-348.
30. Osawa H, Miura Y, Takezawa T, et al. Linked color imaging and blue laser imaging for upper gastrointestinal screening. Clin Endosc 2018;51:513-526.